{"id":"ia-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":null,"effect":"Hemorrhagic cystitis (ifosfamide-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The IA regimen combines ifosfamide, an alkylating agent that cross-links DNA strands, with doxorubicin, a topoisomerase II inhibitor and intercalating agent. Together, these agents create multiple forms of DNA damage that overwhelm cancer cell repair mechanisms and trigger apoptosis. This combination is commonly used in sarcoma and other solid tumors.","oneSentence":"IA regimen is a chemotherapy combination that uses ifosfamide and doxorubicin to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:21.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Soft tissue sarcoma"},{"name":"Osteosarcoma"},{"name":"Other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT03970278","phase":"","title":"Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2019-07-15","conditions":"Glycogen Storage Disease Type IA, Von Gierke's Disease (GSD Type Ia)","enrollment":12},{"nctId":"NCT02515110","phase":"NA","title":"Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2015-08-04","conditions":"Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma","enrollment":137},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT06717750","phase":"PHASE1","title":"A Study of CSCJC3456 in Patients With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","startDate":"2025-02-13","conditions":"Advanced Malignant Solid Tumors","enrollment":102},{"nctId":"NCT07368127","phase":"PHASE1","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","startDate":"2026-03-01","conditions":"Advanced Malignant Solid Tumors","enrollment":112},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT07314541","phase":"PHASE1","title":"A Phase Ia Study of KMY Tablets in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Lei Yunshang Group","startDate":"2025-12-15","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT06229366","phase":"PHASE1","title":"[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-03","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma","enrollment":142},{"nctId":"NCT06070116","phase":"PHASE2","title":"Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-04-05","conditions":"Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular","enrollment":300},{"nctId":"NCT02866136","phase":"PHASE2","title":"Conservative Treatments of Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2012-02","conditions":"Retinoblastoma, Children, Retinal Neoplasm","enrollment":133},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT05458219","phase":"PHASE1","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-10-26","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":470},{"nctId":"NCT03944499","phase":"PHASE1","title":"Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.","status":"COMPLETED","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2019-10-11","conditions":"Solid Tumor, Breast Cancer","enrollment":161},{"nctId":"NCT04018248","phase":"PHASE1","title":"BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2020-04-21","conditions":"Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia","enrollment":26},{"nctId":"NCT05059444","phase":"","title":"ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation","status":"RECRUITING","sponsor":"Guardant Health, Inc.","startDate":"2021-09-07","conditions":"Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma","enrollment":2020},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT00070564","phase":"PHASE3","title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2003-11","conditions":"Breast Cancer","enrollment":3294},{"nctId":"NCT05841498","phase":"NA","title":"Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome","status":"COMPLETED","sponsor":"University Medical Center Mainz","startDate":"2023-05-08","conditions":"Post-COVID-19 Syndrome, Post-COVID Syndrome, Post COVID-19 Condition","enrollment":40},{"nctId":"NCT06669117","phase":"PHASE1, PHASE2","title":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2024-10-22","conditions":"Solid Tumor, MET Alteration","enrollment":140},{"nctId":"NCT07028073","phase":"PHASE1, PHASE2","title":"A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-15","conditions":"Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation","enrollment":78},{"nctId":"NCT06066242","phase":"NA","title":"Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-10-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT03560908","phase":"PHASE1","title":"Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation","status":"WITHDRAWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-07-01","conditions":"Relapsed AML, T(8;21), C-KIT Mutation","enrollment":""},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":"Lymphoblastic Lymphoma, Childhood","enrollment":683},{"nctId":"NCT05789524","phase":"PHASE2","title":"The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B","status":"TERMINATED","sponsor":"ApcinteX Ltd","startDate":"2023-07-06","conditions":"Hemophilia a, Hemophilia B","enrollment":60},{"nctId":"NCT06773091","phase":"PHASE1","title":"A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai NK Cell Technology Co., LTD","startDate":"2025-02-07","conditions":"Advanced Solid Tumors","enrollment":76},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT01705899","phase":"PHASE1","title":"Islet Allotransplantation in Type 1 Diabetes","status":"SUSPENDED","sponsor":"Ohio State University","startDate":"2006-11","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT06760117","phase":"PHASE1","title":"UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Pediatric Solid Tumor","enrollment":39},{"nctId":"NCT06737913","phase":"PHASE2","title":"HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":78},{"nctId":"NCT06677255","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Optics Valley Vcanbiopharma Co., Ltd.","startDate":"2025-01","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":149},{"nctId":"NCT06652685","phase":"PHASE2","title":"Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-10-30","conditions":"Acute Myeloid Leukemia (AML)","enrollment":218},{"nctId":"NCT02965885","phase":"PHASE1","title":"A Study of TAS-116 in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2017-07-10","conditions":"Advanced Solid Tumors","enrollment":31},{"nctId":"NCT06548672","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"Biocity Biopharmaceutics Co., Ltd.","startDate":"2024-06-24","conditions":"Advanced Cancer, Metastatic Solid Tumor","enrollment":148},{"nctId":"NCT02323022","phase":"PHASE3","title":"Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2014-12","conditions":"Acute Myeloid Leukemia","enrollment":618},{"nctId":"NCT06514651","phase":"PHASE1","title":"MAQ-001 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MabQuest SA","startDate":"2024-06-06","conditions":"Advanced Solid Tumor","enrollment":30},{"nctId":"NCT06468215","phase":"NA","title":"Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07","conditions":"Carcinoma, Endometrioid, Fertility Preservation","enrollment":16},{"nctId":"NCT06301425","phase":"NA","title":"MRD Response-adapted Allo-HSCT for Adverse-risk AML","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-05-24","conditions":"Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT06032936","phase":"PHASE1","title":"BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations","status":"TERMINATED","sponsor":"LianBio LLC","startDate":"2023-07-27","conditions":"NSCLC","enrollment":4},{"nctId":"NCT05309512","phase":"PHASE1","title":"Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2022-05-27","conditions":"Advanced Solid Tumor","enrollment":15},{"nctId":"NCT06387134","phase":"NA","title":"Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment","status":"RECRUITING","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2022-12-01","conditions":"Early Stage Lung Adenocarcinoma","enrollment":40},{"nctId":"NCT06345599","phase":"PHASE1, PHASE2","title":"PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-05-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":66},{"nctId":"NCT05991518","phase":"PHASE1, PHASE2","title":"IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors","status":"UNKNOWN","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2023-04-25","conditions":"HER2 Gene Mutation","enrollment":136},{"nctId":"NCT04934514","phase":"PHASE1, PHASE2","title":"Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors","status":"UNKNOWN","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2021-07-06","conditions":"Advanced Solid Tumor","enrollment":97},{"nctId":"NCT06201507","phase":"PHASE2","title":"BV-AVD-R Treatment Children Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2022-10-01","conditions":"Hodgkin Lymphoma","enrollment":44},{"nctId":"NCT05926466","phase":"PHASE2","title":"BTZ-043 Dose Evaluation in Combination and Selection","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2023-09-21","conditions":"Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis","enrollment":90},{"nctId":"NCT05945407","phase":"NA","title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2016-08-01","conditions":"Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I","enrollment":57},{"nctId":"NCT00074165","phase":"PHASE2","title":"Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-01","conditions":"Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma","enrollment":17},{"nctId":"NCT04790448","phase":"PHASE1, PHASE2","title":"Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-27","conditions":"Colorectal Cancer Metastatic","enrollment":37},{"nctId":"NCT02627274","phase":"PHASE1","title":"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-07","conditions":"Solid Tumor, Breast Cancer, Cancer of Head and Neck","enrollment":134},{"nctId":"NCT03517085","phase":"PHASE1, PHASE2","title":"Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2018-05-18","conditions":"GSD1","enrollment":12},{"nctId":"NCT02072356","phase":"EARLY_PHASE1","title":"Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2010-10-11","conditions":"Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer","enrollment":290},{"nctId":"NCT05489848","phase":"PHASE2, PHASE3","title":"Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-08-20","conditions":"Endometrial Cancer","enrollment":294},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT05053425","phase":"NA","title":"Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2021-10-20","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT01547741","phase":"PHASE3","title":"Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2012-04","conditions":"Breast Cancer","enrollment":1871},{"nctId":"NCT03121235","phase":"","title":"PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2017-04-20","conditions":"Aspergillosis, Invasive Pulmonary","enrollment":320},{"nctId":"NCT02438995","phase":"PHASE1","title":"Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2015-05","conditions":"Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck","enrollment":11},{"nctId":"NCT00293475","phase":"PHASE1, PHASE2","title":"Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-10-14","conditions":"Central Nervous System Lymphoma","enrollment":81},{"nctId":"NCT02941523","phase":"PHASE1, PHASE2","title":"Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours","status":"COMPLETED","sponsor":"Noxopharm Limited","startDate":"2017-03-03","conditions":"Cancer","enrollment":19},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT01931358","phase":"PHASE2","title":"Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2013-09-24","conditions":"HIV Infections","enrollment":360},{"nctId":"NCT04201145","phase":"PHASE1","title":"Pembrolizumab + Defactinib In Pleural Mesothelioma","status":"WITHDRAWN","sponsor":"Raphael Bueno, MD","startDate":"2020-09","conditions":"Malignant Pleural Mesothelioma","enrollment":""},{"nctId":"NCT03923777","phase":"NA","title":"Active Surveillance in Early Lung Cancer","status":"UNKNOWN","sponsor":"University of Vermont Medical Center","startDate":"2018-07-31","conditions":"Stage IA Non-small Cell Lung Cancer, Lung Carcinoid Tumor","enrollment":26},{"nctId":"NCT04079010","phase":"NA","title":"The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone","status":"COMPLETED","sponsor":"University of Mary Hardin-Baylor","startDate":"2019-09-04","conditions":"Blood Flow Restriction, Growth Hormone, Strength Outcomes","enrollment":30},{"nctId":"NCT04225195","phase":"PHASE2","title":"Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01","conditions":"Invasive Candidiasis, Invasive Aspergillosis","enrollment":60},{"nctId":"NCT00068601","phase":"PHASE3","title":"S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2003-10","conditions":"Breast Cancer, Infertility, Menopausal Symptoms","enrollment":257},{"nctId":"NCT02304393","phase":"PHASE1","title":"A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-12","conditions":"Solid Tumors","enrollment":140},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT02425813","phase":"PHASE2","title":"Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2015-10","conditions":"Acute Graft Versus Host Disease, Intestinal Graft Versus Host Disease","enrollment":""},{"nctId":"NCT00916708","phase":"NA","title":"Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2008-09","conditions":"Endometrial Cancer","enrollment":1884},{"nctId":"NCT02240875","phase":"PHASE1","title":"A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-09-17","conditions":"Ebola, Ebola Zaire","enrollment":91},{"nctId":"NCT03411109","phase":"","title":"Outcomes of Intrathecal Analgesia in Colorectal Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-10-01","conditions":"Surgery","enrollment":601},{"nctId":"NCT01262560","phase":"PHASE2","title":"Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-02","conditions":"Dysphagia, Lung Cancer, Pain","enrollment":163},{"nctId":"NCT01482377","phase":"PHASE1","title":"A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-12","conditions":"Neoplasms","enrollment":145},{"nctId":"NCT02213861","phase":"PHASE2","title":"Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma","status":"UNKNOWN","sponsor":"TetraLogic Pharmaceuticals","startDate":"2014-11","conditions":"Cutaneous T-Cell Lymphoma (CTCL)","enrollment":60},{"nctId":"NCT00022516","phase":"PHASE3","title":"Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2000-11","conditions":"Breast Cancer","enrollment":1086},{"nctId":"NCT02881749","phase":"PHASE2","title":"Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2016-09","conditions":"Mycosis Fungoides, Cutaneous T-cell Lymphoma","enrollment":68},{"nctId":"NCT00131963","phase":"","title":"A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-10","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT01928147","phase":"PHASE1","title":"A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients","status":"COMPLETED","sponsor":"Presidio Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"Hepatitis C, Chronic","enrollment":114},{"nctId":"NCT02490020","phase":"PHASE1","title":"A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death","status":"UNKNOWN","sponsor":"Qipeng Sun","startDate":"2016-01","conditions":"Disorder Related to Renal Transplantation, Renal Transplant Rejection","enrollment":260},{"nctId":"NCT01889407","phase":"","title":"Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-08","conditions":"Acute Myeloid Leukemia","enrollment":94},{"nctId":"NCT01966224","phase":"PHASE1","title":"A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects","status":"COMPLETED","sponsor":"Immunomic Therapeutics, Inc.","startDate":"2013-09","conditions":"Allergic Rhinoconjunctivitis","enrollment":17},{"nctId":"NCT00424203","phase":"PHASE2","title":"Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2006-01","conditions":"Breast Cancer, Cognitive/Functional Effects, Depression","enrollment":40},{"nctId":"NCT00629278","phase":"PHASE3","title":"Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2007-12","conditions":"Breast Cancer","enrollment":2500},{"nctId":"NCT01799460","phase":"","title":"Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2010-12","conditions":"Idiopathic Membranous Nephropathy","enrollment":80},{"nctId":"NCT00001832","phase":"PHASE2","title":"Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-08","conditions":"Melanoma, Neoplasm Metastasis","enrollment":170},{"nctId":"NCT00712140","phase":"PHASE3","title":"Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer","status":"UNKNOWN","sponsor":"Warwick Medical School","startDate":"2007-10","conditions":"Breast Cancer","enrollment":4000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IA regimen","genericName":"IA regimen","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BC3195 is a small molecule being studied in a Phase Ia/Ib clinical trial for its safety, pharmacokinetics, and antitumor activity in patients with advanced or metastatic cancer. The trial involves dose escalation and expansion of BC3195 in combination with other treatments, including CACAG+VEN and 3+7, for various cancer types.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}